The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (0% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial

详细信息    查看全文

• 作者：Jung Hyun Kwon (1)
  Si Hyun Bae (2)
  Youn Jae Lee (3)
  Jin-Woo Lee (4)
  Young Seok Kim (5)
  Jae Seok Hwang (6)
  Won Young Tak (7)
  Jeong Won Jang (2)
  Byung Seok Lee (8)
  June Sung Lee (9)
  Chun Kyon Lee (10)
  Soon Koo Baik (11)
  Neung Hwa Park (12)
  Tae Hee Lee (13)
  Dong Joon Kim (14)
  Jae-Seok Choi (15)
  Jae-Gook Shin (15) (16)
  Hyeon Woo Yim (17)
  
• 关键词：Chronic hepatitis C ; Genotype 1 ; Interferon dosing ; Polymorphism ; IL28B
• 刊名：Hepatology International
• 出版年：2013
• 出版时间：October 2013
• 年：2013
• 卷：7
• 期：4
• 页码：1000-1009
• 全文大小：
• 作者单位：Jung Hyun Kwon (1)
  Si Hyun Bae (2)
  Youn Jae Lee (3)
  Jin-Woo Lee (4)
  Young Seok Kim (5)
  Jae Seok Hwang (6)
  Won Young Tak (7)
  Jeong Won Jang (2)
  Byung Seok Lee (8)
  June Sung Lee (9)
  Chun Kyon Lee (10)
  Soon Koo Baik (11)
  Neung Hwa Park (12)
  Tae Hee Lee (13)
  Dong Joon Kim (14)
  Jae-Seok Choi (15)
  Jae-Gook Shin (15) (16)
  Hyeon Woo Yim (17)
  
  1. Department of Internal Medicine, Incheon St. Mary Hospital, The Catholic University of Korea, Incheon, Korea
  2. Department of Internal Medicine, Seoul St. Mary Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-040, Korea
  3. Department of Internal Medicine, Pusan Paik Hospital, Inje University of Korea, Gaegum-dong 633-165, Busanjin-gu, Pusan, 614-735, Korea
  4. Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea
  5. Department of Internal Medicine, Bucheon Soonchunhyang Hospital, Soonchunhyang University of Korea, Bucheon, Korea
  6. Department of Internal Medicine, Dongsan Hospital, Keimyung University of Korea, Taegu, Korea
  7. Department of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University of Korea, Taegu, Korea
  8. Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University of Korea, Taejon, Korea
  9. Department of Internal Medicine, Ilsan Paik Hospital, Inje University of Korea, Ilsan, Korea
  10. Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Ilsan, Korea
  11. Department of Internal Medicine, Wonju Christian Hospital, Yonsei University of Korea, Wonju, Korea
  12. Department of Internal Medicine, Ulsan University Hospital, Ulsan University of Korea, Ulsan, Korea
  13. Department of Internal Medicine, Konyang University Hospital, Konyang University of Korea, Taejon, Korea
  14. Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University of Korea, Chuncheon, Korea
  15. Department of Pharmacology and PharmacoGenomics Research Center, Inje University of Korea, Pusan, Korea
  16. Department of Clinical Pharmacology, Busan Paik Hospital, Inje University of Korea, Pusan, Korea
  17. Clinical Research Coordinating Center for Catholic Medical Center, The Catholic University of Korea, Seoul, Korea
  
• ISSN：1936-0541

文摘

Purpose A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. Methods A total of 178 treatment-nave patients with CHC genotype 1 were prospectively enrolled. All patients were randomly assigned to treatment with one of two peginterferon alfa-2a regimens: 180 per week for 48weeks (full-dose group) or 180 per week during the first 12weeks followed by 135 per week for the next 36weeks (dose-reduction group). Polymorphisms related to IL28B, ITPA, C20orf194 and SLC29A1 were studied. Results SVR rates did not differ between the full-dose and dose-reduction groups (56.5 and 51.2%, respectively, p=0.474). The frequency of additional reductions of the peginterferon dose because of adverse events was higher in the full-dose group than in the dose-reduction group. SVR rates in patients homozygous for the IL28B major allele were higher than those in patients for the other IL28B alleles. For patients with unfavorable IL28B genotypes, SVR was less likely to be achieved in the dose-reduction group than in the full-dose group. Conclusions In Koreans with HCV genotype 1, the virological response to treatment did not differ between a full dose and reduced dose (0% of full dose) of peginterferon alfa-2a. However, in the patients with unfavorable IL28B genotypes, the full-dose treatment of peginterferon alfa-2a may be beneficial.